
Andexanet alfa rapidly reduces anti-Xa activity and improves hemostatic efficacy in ICH patients on factor Xa inhibitors, despite an increased risk of thrombotic events.


coremsg

While the new drug reduced hematoma expansion compared with usual care, it was also associated with an increase in thrombotic events in the ANNEXa-I study.

Andexanet Aids Hemostasis in ICH Tied to FXa Inhibitors

andexanet-alfa-in-ich-with-fxa-inhibitors


Andexanet Alfa in ICH with FXa Inhibitors
